Menopause Racial and Ethnic Disparities: What the Evidence Shows

The SWAN Study: The Primary Evidence Base for Racial Differences in Menopause

The Study of Women's Health Across the Nation is the single most important source of race-stratified menopause data available. Launched in 1996 across seven U.S. Sites, SWAN enrolled 3,302 women aged 42 to 52 years from five self-identified racial and ethnic groups: white, Black, Hispanic, Chinese, and Japanese. Follow-up has continued for nearly three decades, generating more than 350 published papers.

What SWAN Was Designed to Answer

SWAN was explicitly built to test whether the menopausal experience differed by race, ethnicity, and socioeconomic position. The study's design allowed researchers to separate biological differences from confounders such as body mass index, smoking status, and access to care. Its longitudinal structure means findings reflect changes within women over time, not just snapshots.

Key SWAN Findings on Age at Final Menstrual Period

Black women in SWAN reached the final menstrual period at a median age of 49.3 years, roughly two years earlier than white women at 51.4 years. Hispanic women fell in between at approximately 50.1 years. Earlier natural menopause is independently associated with increased all-cause mortality, cardiovascular disease, and osteoporosis, so this two-year gap carries real clinical weight [1].

Limitations Clinicians Should Know

SWAN intentionally excluded women who were already postmenopausal at enrollment, which may underestimate the prevalence of very early menopause in the most socioeconomically disadvantaged subgroups. Indigenous women are also not represented, a gap addressed separately in the Strong Heart Study and its ancillary analyses.

Vasomotor Symptoms: Who Gets Them, How Severe, and How Long

Vasomotor symptoms (VMS), meaning hot flashes and night sweats, are the defining complaint of the menopausal transition. Their frequency, severity, and duration vary substantially by race.

Prevalence by Race at SWAN Baseline

At the first SWAN interview, 45.6% of Black women reported frequent VMS compared with 31.2% of white women, 35.4% of Hispanic women, 20.5% of Chinese women, and 17.6% of Japanese women [2]. That ordering has remained consistent across follow-up waves. Black women are not just more likely to report hot flashes; they rate them as more bothersome on validated scales including the Hot Flash Related Daily Interference Scale.

Duration of Symptoms

The Penn Ovarian Aging Study and SWAN longitudinal data converge on a striking finding: Black women experience vasomotor symptoms for a median of 10.1 years, compared with 6.5 years for white women [3]. The Study of Women's Health Across the Nation Health reported in 2015 that "the duration of frequent VMS was longest for Black women and shortest for Japanese and Chinese women," a gradient that persisted after adjusting for BMI, smoking, education, and anxiety [3].

Why the Difference Exists

Several mechanisms have been proposed. Higher rates of chronic psychosocial stress raise sympathetic tone and lower the thermoregulatory neutral zone. Differences in adiposity distribution matter because peripheral aromatization of androgens to estrogen in adipose tissue may buffer VMS in women with central obesity, but this buffering effect appears weaker in Black women than in white women after statistical adjustment. Genetic variation in the ESR1 gene (estrogen receptor alpha) and the CYP19A1 aromatase gene may also contribute, though genome-wide association studies in diverse populations remain underpowered [4].

Cardiovascular Risk During the Menopausal Transition

The Steepest Rise in Subclinical Atherosclerosis

Carotid intima-media thickness (CIMT) increases in all women during the menopausal transition, but SWAN data show the steepest trajectory in Black women. Investigators reported that Black race was independently associated with greater CIMT progression over 10 years even after controlling for traditional Framingham risk factors, blood pressure, and lipid levels [5]. This finding suggests menopause-related estrogen withdrawal compounds pre-existing cardiovascular vulnerability in a group already carrying higher baseline risk.

Blood Pressure Trajectories

Systolic blood pressure rises roughly 5 to 6 mmHg across the perimenopause in all racial groups in SWAN, but the rise begins from a higher baseline in Black women. Hypertension prevalence in Black women aged 40 to 59 is approximately 47%, compared with 30% in white women of the same age range, per CDC data [6]. The menopausal transition therefore pushes many Black women past clinical thresholds that trigger additional cardiovascular risk.

Metabolic Syndrome and Insulin Resistance

Insulin resistance worsens during the late perimenopausal transition across all groups, but Hispanic women show a steeper increase in fasting insulin and HOMA-IR scores than white women during the same transition period in SWAN ancillary metabolic analyses. This finding is consistent with the higher lifetime prevalence of type 2 diabetes in Hispanic women and underlines the need for earlier metabolic screening at the first signs of menstrual irregularity [7].

Bone Health: A More Complicated Picture Than DXA Suggests

Lower Baseline BMD in Asian Women

Chinese and Japanese women in SWAN start the menopausal transition with lower lumbar spine and total hip bone mineral density (BMD) than white women, a difference averaging 0.05 to 0.08 g/cm2. Despite this, fracture incidence in Asian American women is not proportionally higher. The explanation may lie in bone geometry: Asian women tend to have shorter hip-axis length, which biomechanically reduces fracture risk per unit of BMD lost [8].

Black Women and the Fracture Paradox

Black women have the highest average BMD of any group in SWAN and the lowest age-adjusted hip fracture rate in U.S. Population data. The National Osteoporosis Foundation's 2023 guidelines note that standard FRAX scores may underestimate fracture risk in Black women because the algorithm was calibrated primarily on white cohorts [9]. When Black women do fracture, they receive less aggressive follow-up care and have higher 12-month post-fracture mortality than white women, a pattern documented in Medicare claims analyses.

Hormone Therapy Access and the Prescribing Gap

The Magnitude of the Gap

Black and Hispanic women are 40 to 60% less likely to be offered or prescribed hormone therapy (HRT) than white women presenting with equivalent symptom burden in primary care settings. A 2021 analysis of commercial insurance claims covering 2.1 million women aged 45 to 64 found that white women were prescribed menopausal hormone therapy at a rate of 8.4 per 100 visits, compared with 4.9 per 100 visits for Black women and 5.1 per 100 visits for Hispanic women, adjusting for comorbidities and visit type [10].

Why the Gap Persists

Multiple factors contribute. Clinician-level implicit bias leads to symptom minimization. The 2002 Women's Health Initiative scare disproportionately reduced HRT prescribing in all groups, but Black and Hispanic women were less likely to have their concerns revisited by a physician as evidence evolved. Health system structural barriers, including shorter appointment times in safety-net settings, limit counseling depth. Mistrust of the medical system, rooted in a documented history of medical experimentation on Black women specifically, creates patient-side hesitancy that clinicians rarely address directly [11].

What the Menopause Society Says

The Menopause Society (formerly NAMS) 2023 position statement affirms that "for women aged younger than 60 years or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS" [12]. The statement does not stratify this recommendation by race, which means clinicians should apply it equally across racial groups while accounting for individual cardiovascular and thrombotic risk profiles.

Sleep Disparities During the Menopausal Transition

Objective vs. Subjective Discordance in Asian Women

Asian women in SWAN self-report the lowest rates of insomnia, yet actigraphy and polysomnography data from SWAN ancillary studies show that Chinese and Japanese women have higher rates of objectively measured sleep-disordered breathing and lower sleep efficiency than white women of similar BMI [13]. This discordance likely reflects cultural norms around symptom reporting and stoicism rather than a true absence of sleep pathology.

Night Sweats and Sleep Fragmentation in Black Women

Black women report significantly higher rates of night-sweat-related sleep disruption than white women in SWAN diary data. Night-sweat-driven awakenings fragment slow-wave sleep and reduce REM sleep, which has downstream effects on cortisol regulation, insulin sensitivity, and mood. Given that Black women already carry higher rates of depression during the menopausal transition, sleep fragmentation functions as both a symptom and an amplifier of other health risks [14].

Mental Health and Mood: The Depression Gap

Depression during perimenopause is two to four times more common in women with a prior depressive episode. Black women have lower lifetime rates of diagnosed depression than white women in epidemiological surveys, but this reflects underdiagnosis rather than lower true prevalence. SWAN data show that Black women score equivalently or higher on the Center for Epidemiologic Studies Depression Scale (CES-D) compared with white women during the late perimenopause, despite lower rates of formal mental health service use [15].

Hispanic women in SWAN report the highest CES-D scores of any group during the perimenopause, with acculturation stress and social isolation identified as independent contributors beyond hormonal status. A 2022 paper in Menopause found that nativity (foreign-born vs. U.S.-born) modified the relationship between menopausal status and depressive symptoms in Hispanic women, a nuance absent from most clinical screening protocols [15].

Indigenous Women: A Population Missing from Most Research

The Strong Heart Study, which followed 4,549 American Indian adults from 13 communities across three U.S. Regions, provides the best available data on cardiovascular trajectories in Indigenous midlife women. Indigenous women in the Strong Heart cohort show extremely high rates of metabolic syndrome (exceeding 60% in some communities), hypertension, and diabetes entering the menopausal transition, a burden that dwarfs that seen in any SWAN subgroup [16].

Virtually no large-scale, race-stratified VMS prevalence data exist for Indigenous women. The absence is not evidence of absence; it reflects chronic underinvestment in this population's research infrastructure. Clinicians caring for Indigenous women should screen aggressively for cardiovascular and metabolic comorbidities at the first sign of menstrual irregularity, rather than waiting for full menopause to be established.

Socioeconomic Status: Confounding or Independent Driver?

A recurring debate in the menopause disparities literature asks whether racial differences in symptom burden and health outcomes disappear after controlling for socioeconomic status (SES). The short answer: they do not.

SWAN analyses that stratified by education level and income found that racial differences in VMS prevalence and duration persisted within SES strata. Black women with college degrees still reported longer VMS duration than white women without college degrees [17]. This finding supports the concept of "weathering," proposed by researcher Arline Geronimus, which holds that chronic exposure to structural racism accelerates biological aging independently of classic SES measures. Higher allostatic load in Black women, measured by a composite of inflammatory markers, cortisol, and cardiovascular indicators, partly mediates the racial differences in VMS burden [17].

Clinical Recommendations for Equitable Menopause Care

Screening and Symptom Assessment

Clinicians should use validated tools such as the Menopause Rating Scale or the Greene Climacteric Scale with all patients regardless of race. Do not rely on spontaneous symptom disclosure; Black and Hispanic women are less likely to volunteer symptoms unprompted, not because symptoms are absent but because of historical and cultural barriers to disclosure.

Hormone Therapy Prescribing

Apply the Menopause Society's 2023 criteria uniformly. For women with clear VMS and no contraindications, race alone is not a reason to withhold HRT. Individualize based on cardiovascular risk, venous thromboembolism history, and breast cancer risk, factors that may be elevated in specific individuals of any background but should not be assumed based on race.

Cardiovascular Monitoring

Given the steeper CIMT progression in Black women and the higher metabolic risk in Hispanic women, annual fasting glucose, lipid panels, and blood pressure monitoring should begin at age 40 for women in these groups who show any perimenopausal symptoms, rather than at the standard age 45 to 50 thresholds commonly applied [5, 6].

Bone Health Screening

FRAX scores systematically underestimate fracture risk in Black women. Until FRAX is recalibrated with diverse population data, clinicians should consider DXA scanning at lower thresholds (e.g., a T-score of -1.5 rather than -2.5 as the trigger for pharmacotherapy discussion) for Black patients with additional clinical risk factors, per the National Osteoporosis Foundation's 2023 guidance [9].